ClinicalTrials.gg
CompletedNCT00479232Updated Sep 21, 2015Results posted

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

A Phase 1 interventional study of vorinostat and decitabine in Leukemia, Myelocytic, Acute Myelodysplastic Syndromes and Myelodysplastic Syndromes, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
71
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vorinostat in Leukemia — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Leukemia.

Started
2007
the only one that year
Phase 1
4 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing vorinostat in Leukemia, this one is the only one that started in 2007, is one of 4 in phase 1, and was the 2nd registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

None of the 10 studies testing vorinostat in Leukemia is open now. The open studies under Leukemia, anywhere →

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing vorinostat in Leukemia as a file.
02

Study summary

This study is to evaluate the safety and tolerability of vorinostat in combination with decitabine as well as the in vivo molecular and biological effects of vorinostat in patients with refractory or relapsed Acute Myelogenous Leukemia (AML) and intermediate or high risk as defined by International Prognostic Scoring System (IPSS) Myelodysplastic Syndrome (MDS). Participants with Acute Myelogenous Leukemia or Myelodysplastic Syndrome are eligible.

03

Conditions studied

  • Leukemia, Myelocytic, Acute Myelodysplastic Syndromes
  • Myelodysplastic Syndromes

Keywords

  • Leukemia
  • Myelocytic
  • Acute Myelodysplastic Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is at least 18 years old with /relapsed AML

    • If untreated AML, patient is older than 60 years old and not a candidate for standard chemotherapy
  • Patient is at least 4 weeks from prior treatment and has recovered from all prior treatment side effects
  • Patient has no known liver or kidney problems
  • Patient knows of no reason they can not receive transfusions of blood clotting cells ()
  • Patient is able to swallow capsules
  • Patients both male and female are willing to practice during the study

Exclusion criteria

Exclusion Criteria:

  • Patient has received prior treatment with valproic acid, decitabine or azacitidine
  • Being is less than 18 years of age or if patient has untreated AML is below 60 years of age
  • Patient is a women who is pregnant or breastfeeding. Patient has an active infection that requires antibiotics
  • Patient has uncontrolled illness including but not limited to the following: heart problems (congestive heart failure, unstable angina pectoris, cardiac arrhythmia), inflammation of the pancreas; a mental or social condition that may interfere with patient following study procedures
  • Patient has known (HIV) infection or HIV-related . Patient has a known history of or C infection
  • Patient currently has another active cancer other than certain types of skin cancer
  • Patient is heterosexual and able to have a child and is unwilling to practice during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Cohort 1: Vorinostat (sequential)

    Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment. Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.

    Drug: vorinostat · Drug: decitabine

  • Experimental
    Cohort 2: Vorinostat (concurrent)

    Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles. Decitabine IV 20 mg/m\^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment.

    Drug: vorinostat · Drug: decitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events

    Participants who received at least one dose of vorinostat in combination with decitabine intravenous (IV) at a dose of 20 mg/m\^2 daily for 5 days along with oral vorinostat 400 mg once daily for 7 to 14 days in a 28-day cycle concurrently or sequentially, were evaluated to determine the maximum tolerable dose (MTD) determined by the number of participants experiencing dose limiting toxicity (DLT) events defined as any Grade 3 or 4 non-hematological toxicity (reported adverse event) and/or myelosuppression lasting \>42 days.

    Time frame: Day 1 to 28 of Cycle 1

Other outcomes

  1. Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)

    Objective Response Rate was measured in participants with refractory or relapse AML (acute myelogenous leukemia) in combination with Decitabine who were treated with vorinostat and decitabine on either a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for Myelodysplastic Syndrome (MDS) participants.

    Time frame: Approximately 6 months

  2. Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)

    Objective Response Rate was measured in participants with intermediate-high risk MDS or untreated AML who were treated with vorinostat and decitabine either on a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for MDS participants.

    Time frame: Approximately 6 months

07

Results

Posted Aug 31, 2011

Participant flow

Participant flow — Overall Study
MilestoneConcurrent, Vorinostat 400mg qd x 7d/4wk + DecitabineConcurrent, Vorinostat 400mg qd x 7d/2wk + DecitabineConcurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)Sequential, Vorinostat 400mg qd x 7d/4wk + DecitabineSequential, Vorinostat 400mg qd x 10d/4wk + DecitabineSequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)
Started33283430
Completed000000
Not completed33283430
Withdrew: Adverse event0050010
Withdrew: Deviation from protocol001000
Withdrew: Lack of efficacy002004
Withdrew: Physician decision002001
Withdrew: Progressive disease31123312
Withdrew: Withdrew consent026013

Outcome measures

PrimaryNumber of Participants Experiencing Dose Limiting Toxicity (DLT) Events

Participants who received at least one dose of vorinostat in combination with decitabine intravenous (IV) at a dose of 20 mg/m\^2 daily for 5 days along with oral vorinostat 400 mg once daily for 7 to 14 days in a 28-day cycle concurrently or sequentially, were evaluated to determine the maximum tolerable dose (MTD) determined by the number of participants experiencing dose limiting toxicity (DLT) events defined as any Grade 3 or 4 non-hematological toxicity (reported adverse event) and/or myelosuppression lasting \>42 days.

Time frame:
Day 1 to 28 of Cycle 1
Reported as:
Number · participants
Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events
participantsConcurrent, Vorinostat 400mg qd x 7d/4wk + DecitabineConcurrent, Vorinostat 400mg qd x 7d/2wk + DecitabineConcurrent, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)Sequential, Vorinostat 400mg qd x 7d/4wk + DecitabineSequential, Vorinostat 400mg qd x 10d/4wk + DecitabineSequential, Vorinostat 400mg qd x 14d/4wk + Decitabine (MTD)
Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events000001
Other pre-specifiedObjective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)

Objective Response Rate was measured in participants with refractory or relapse AML (acute myelogenous leukemia) in combination with Decitabine who were treated with vorinostat and decitabine on either a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for Myelodysplastic Syndrome (MDS) participants.

Time frame:
Approximately 6 months
Reported as:
Number · percentage of participants
Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)
percentage of participantsRefractory or Relapsed AML, ConcurrentRefractory or Relapsed AML, Sequential
Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Refractory or Relapse Acute Myelogenous Leukemia (AML)7.1 ± 00.0 ± NA
Other pre-specifiedObjective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)

Objective Response Rate was measured in participants with intermediate-high risk MDS or untreated AML who were treated with vorinostat and decitabine either on a concurrent or sequential regimen. The Objective response was defined as any confirmed complete remission or any confirmed partial remission for AML participants and complete remission, confirmed partial remission or confirmed hematologic improvement for MDS participants.

Time frame:
Approximately 6 months
Reported as:
Number · percentage of participants
Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)
percentage of participantsUntreated AML or Intermediate, ConcurrentUntreated AML or Intermediate, Sequential
Objective Response Rate in Participants Treated With Vorinostat + Decitabine With Intermediate-high Risk Myelodysplastic Syndrome (MDS) or Untreated Acute Myelogenous Leukemia (AML)35.0 ± 170.313.6 ± 119.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Concurrent, Vorinostat 400 mg qd x 7d/4wk + Decitabine—3/3 (100%)3/3 (100%)
Concurrent, Vorinostat 400 mg qd x 7d/2wk + Decitabine—1/3 (33.3%)3/3 (100%)
Concurrent, Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD)—21/28 (75%)27/28 (96.4%)
Sequential, Vorinostat 400 mg qd x 7d/4wk + Decitabine—2/3 (66.7%)3/3 (100%)
Sequential, Vorinostat 400 mg qd x 10d/4wk + Decitabine—4/4 (100%)4/4 (100%)
Sequential,Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD)—25/31 (80.6%)29/31 (93.5%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventConcurrent, Vorinostat 400 mg qd x 7d/4wk + DecitabineConcurrent, Vorinostat 400 mg qd x 7d/2wk + DecitabineConcurrent, Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD)Sequential, Vorinostat 400 mg qd x 7d/4wk + DecitabineSequential, Vorinostat 400 mg qd x 10d/4wk + DecitabineSequential,Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD)
PneumoniaInfections and infestations3/30/36/280/32/41/31
Atrial fibrillationCardiac disorders2/30/30/280/30/41/31
Febrile neutropeniaBlood and lymphatic system disorders1/31/312/281/31/47/31
Pericardial effusionCardiac disorders1/30/30/280/31/40/31
Sinus bradycardiaCardiac disorders1/30/30/280/30/40/31
CaecitisGastrointestinal disorders0/30/30/281/30/40/31
NauseaGastrointestinal disorders1/30/31/280/30/41/31
PancreatitisGastrointestinal disorders1/30/30/280/30/40/31
DeathGeneral disorders1/30/30/280/30/40/31
Multi-organ failureGeneral disorders0/31/30/280/30/40/31
Most frequent other events
Showing 10 of 169
Most frequent other events
EventConcurrent, Vorinostat 400 mg qd x 7d/4wk + DecitabineConcurrent, Vorinostat 400 mg qd x 7d/2wk + DecitabineConcurrent, Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD)Sequential, Vorinostat 400 mg qd x 7d/4wk + DecitabineSequential, Vorinostat 400 mg qd x 10d/4wk + DecitabineSequential,Vorinostat 400 mg qd x 14d/4wk + Decitabine (MTD)
NeutropeniaBlood and lymphatic system disorders0/33/39/280/30/46/31
Sinus tachycardiaCardiac disorders3/30/31/281/31/40/31
DiarrhoeaGastrointestinal disorders2/33/316/281/33/415/31
NauseaGastrointestinal disorders2/31/317/283/33/420/31
FatigueGeneral disorders3/31/311/282/33/419/31
HypocalcaemiaMetabolism and nutrition disorders0/30/32/283/30/42/31
HypophosphataemiaMetabolism and nutrition disorders2/31/34/283/32/41/31
HeadacheNervous system disorders3/32/37/281/30/45/31
ConstipationGastrointestinal disorders2/30/316/281/33/411/31
DyspepsiaGastrointestinal disorders1/30/31/280/33/41/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vorinostat + Decitabine, ConcurrentVorinostat + Decitabine, SequentialTotal
Mean63.9 ± 13.066.6 ± 13.865.3 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat + Decitabine, ConcurrentVorinostat + Decitabine, SequentialTotal
Female111829
Male231942
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016. Epub 2014 Jul 8. PubMed 25040094 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Apr 2010 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 28, 2007
Start
Jun 2007
Primary completionActual
Apr 2010
CompletionActual
Mar 2012
Results first posted
Aug 31, 2011
Last update
Sep 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00479232
Responsible party
Sponsor
First posted
May 28, 2007
Start date
Jun 2007
Primary completion
Apr 2010
Completion
Mar 2012
Results posted
Aug 31, 2011
Last update
Sep 21, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorinostat · Decitabine

Start the discussion